Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib Plus Humanized Programmed Death Receptor-1 in Patients with High-Risk Advanced Hepatocellular Carcinoma: A Real-World Study
Xu Chang,Huiyong Wu,Shangkun Ning,Xinge Li,Yinfa Xie,Wenbo Shao,Jinming Yu
DOI: https://doi.org/10.2147/JHC.S418387
2023-09-07
Journal of Hepatocellular Carcinoma
Abstract:Xu Chang, 1, 2 Huiyong Wu, 2 Shangkun Ning, 3 Xinge Li, 4 Yinfa Xie, 2 Wenbo Shao, 2 Jinming Yu 1, 5 1 Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300000, People's Republic of China; 2 Department of Interventional Therapy II, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, People's Republic of China; 3 Department of Interventional Therapy I, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, People's Republic of China; 4 Department of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250117, People's Republic of China; 5 Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, 250117, People's Republic of China Correspondence: Jinming Yu, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300000, People's Republic of China, Tel +86 531-67626306, Email Wenbo Shao, Department of Interventional Therapy II, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, People's Republic of China, Tel +86 531-67626892, Email Purpose: The treatment of hepatocellular carcinoma (HCC) patients with high-risk features (Vp4, and/or tumor occupancy≥ 50%) has not been standardized and has poor outcomes. The present study aimed to assess the safety, efficacy, and prognostic impact of lenvatinib, hepatic arterial infusion chemotherapy (HAIC), and humanized programmed death receptor-1 (PD-1) in treating high-risk patients and to explore the biomarkers that may predict the efficacy. Methods: HCC patients with high-risk features treated with lenvatinib, HAIC, and PD-1 were analyzed retrospectively. Overall survival (OS), progression-free survival (PFS), duration of response (DOR), objective response rate (ORR), and disease control rate (DCR) were calculated to evaluate the antitumor efficacy. Treatment-related adverse events (TRAEs) were analyzed to assess the safety profiles. Results: Between February 2020 and July 2022, 97 patients were enrolled in this retrospective cohort study. The median follow-up time was 447 days. During analysis, 65 patients had disease progression, and 39 patients died. The median PFS and OS were 295 and 579 days, respectively. According to RECIST 1.1 and mRECIST, the ORR was 64.9% and 78.3%, respectively, and the DCR was 92.8%. The median and intrahepatic DOR was 363 and 462 days, respectively. Treatment-related grade 3 or 4 adverse events occurred in 64 (65.9%) patients, and the most common adverse events were hypertension (9.3%), thrombocytopenia (7.2%), and elevated aspartate transaminase (7.2%). Participants with low levels of serum procalcitonin (PCT) had satisfactory prognosis. Conclusion: Lenvatinib, HAIC, and PD-1 were safe and showed promising antitumor activity against HCC with high-risk features. The initial levels of procalcitonin might be the predictive biomarkers for the combined treatment. Keywords: hepatocellular carcinoma, HAIC, lenvatinib, VP4, PD-1 Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related deaths worldwide. 1,2 About 72% of cases of HCC occur in Asia, and >50% occur in China. 3 Most patients present advanced, unresectable disease, with a poor 5-year survival probability of approximately 10–18%. 4,5 Tyrosine kinase inhibitors (TKIs) such as sorafenib (SHARP and Asia-Pacific) and lenvatinib (REFLECT) have been approved as first-line systemic therapies for unresectable advanced HCC. Recently, the Food and Drug Administration (FDA) approved the combination of atezolizumab and bevacizumab for patients with unresectable or metastatic HCC who have not received prior systemic therapy, based on Phase III IMbrave150 study. 6–8 Various guidelines recommend it as the preferred first-line treatment because of its outstanding results. However, the recently updated IMbrave150 showed that this treatment has limited benefit in high-risk patients [Vp4, and/or tumor occupancy≥50% (TO≥ -Abstract Truncated-
oncology